blarcamesine-axon

Blarcamesine (AXON) Trial

Overview

Blarcamesine (formerly known as AXON-205) is an experimental drug that acts as a dual-function molecular entity, functioning as a muscarinic receptor agonist and sigma-1 receptor modulator. It has been investigated for potential neuroprotective effects in Alzheimer's disease (AD) and other neurodegenerative conditions, representing a multi-target therapeutic approach that addresses several pathophysiological pathways simultaneously[@blarcamesine2023].

The drug was developed through a rational drug design process targeting the cholinergic system, which is prominently affected in Alzheimer's disease, while simultaneously engaging the sigma-1 receptor system known for its neuroprotective properties. This dual mechanism distinguishes blarcamesine from earlier cholinergic agents that targeted only single receptors[@muscarinic2022].

Trial Details

Clinical Trial Information

| Parameter | Details |
|-----------|---------|
| Drug Name | Blarcamesine (AXON-205, previously designated as EVT 301) |
| ClinicalTrials.gov Identifier | NCT05320630 |
| Phase | Phase 2/3 |
| Status | Completed |
| Sponsor | Axon Neuroscience SE |
| Study Period | 2022-2024 |
| Patient Population | Patients with early Alzheimer's disease or mild cognitive impairment due to AD |
| Route of Administration | Oral |

Development History

Blarcamesine (AXON) Trial

Overview

Blarcamesine (formerly known as AXON-205) is an experimental drug that acts as a dual-function molecular entity, functioning as a muscarinic receptor agonist and sigma-1 receptor modulator. It has been investigated for potential neuroprotective effects in Alzheimer's disease (AD) and other neurodegenerative conditions, representing a multi-target therapeutic approach that addresses several pathophysiological pathways simultaneously[@blarcamesine2023].

The drug was developed through a rational drug design process targeting the cholinergic system, which is prominently affected in Alzheimer's disease, while simultaneously engaging the sigma-1 receptor system known for its neuroprotective properties. This dual mechanism distinguishes blarcamesine from earlier cholinergic agents that targeted only single receptors[@muscarinic2022].

Trial Details

Clinical Trial Information

| Parameter | Details |
|-----------|---------|
| Drug Name | Blarcamesine (AXON-205, previously designated as EVT 301) |
| ClinicalTrials.gov Identifier | NCT05320630 |
| Phase | Phase 2/3 |
| Status | Completed |
| Sponsor | Axon Neuroscience SE |
| Study Period | 2022-2024 |
| Patient Population | Patients with early Alzheimer's disease or mild cognitive impairment due to AD |
| Route of Administration | Oral |

Development History

Blarcamesine emerged from a drug development program focused on creating compounds that could address multiple aspects of Alzheimer's disease pathology. The compound was initially designated as EVT 301 during early development stages before being reformulated and rebranded as AXON-205[@blarcamesine2023].

The transition from EVT 301 to AXON-205 involved optimization of the pharmaceutical formulation to improve bioavailability and dosing convenience. Axon Neuroscience SE, a European biotech company specializing in tau-targeted therapies, advanced this compound through clinical development[@fisher2022].

Mechanism of Action

Blarcamesine exerts its neuroprotective effects through two primary molecular targets, creating a synergistic approach to neuroprotection:

Muscarinic M1 Receptor Agonism

The muscarinic acetylcholine receptor system plays a critical role in cognitive function, and M1 receptors are particularly important for memory and learning processes. Blarcamesine acts as a selective M1 muscarinic receptor agonist, triggering downstream signaling cascades that promote neuronal survival and cognitive enhancement[@smith2021].

Downstream Signaling Pathways

Upon M1 receptor activation by blarcamesine, the following intracellular pathways are engaged:

Cognitive Enhancement Effects

The cognitive benefits of M1 muscarinic receptor agonism include:

• Memory Consolidation: Enhanced cholinergic signaling supports the formation and retention of new memories
• Attention and Learning: Improved cortical cholinergic tone facilitates attention processes critical for learning
• Synaptic Plasticity: M1 activation promotes changes in synaptic strength necessary for cognitive function
• Neuroprotection: Anti-apoptotic signaling protects cholinergic neurons from degeneration[@brown2022]

Effects on Tau Pathology

Emerging evidence suggests that muscarinic M1 receptor activation may directly influence tau pathology, a key hallmark of Alzheimer's disease. M1 agonism has been shown to:

• Reduce tau phosphorylation at multiple epitopes
• Decrease tau aggregation propensity
• Enhance tau clearance through autophagy pathways
• Protect against tau-induced synaptic dysfunction[@caccamo2019]

Sigma-1 Receptor Modulation

The sigma-1 receptor is an endoplasmic reticulum-resident protein with chaperone functions that become particularly important under cellular stress conditions. Blarcamesine acts as a sigma-1 receptor agonist, enhancing its neuroprotective functions[@sigma12022].

Sigma-1 Receptor Biology

The sigma-1 receptor operates as a calcium-sensitive chaperone that:

• Modulates endoplasmic reticulum calcium homeostasis
• Supports mitochondrial function under stress
• Protects against oxidative damage
• Promotes neuronal resilience to various insults[@herrerogr2022]

Neuroprotective Mechanisms

Sigma-1 receptor activation by blarcamesine provides protection through:

Integration with Muscarinic Effects

The dual-target nature of blarcamesine creates opportunities for synergistic neuroprotection:

• M1 agonism provides acute cognitive enhancement and anti-apoptotic signaling
• Sigma-1 modulation offers long-term cellular protection and stress resilience
• Together, they address both symptomatic and disease-modifying aspects of neurodegeneration[@wu2021]

Effects on Amyloid Pathology

While primarily targeting cholinergic and sigma-1 pathways, blarcamesine may also influence amyloid pathology through indirect mechanisms:

• Cholinergic signaling can modulate amyloid precursor protein processing
• Reduced neuronal stress decreases amyloidogenic pathway activation
• Improved cellular homeostasis supports non-amyloidogenic processing[@chen2021]

Clinical Trial Design

Trial Phases

The blarcamesine AXON trial program consisted of multiple phases:

Phase 1 Studies

Initial Phase 1 studies established:

• Safety and tolerability in healthy volunteers
• Pharmacokinetic profile
• Maximum tolerated dose
• Dose selection for Phase 2

Phase 2 Trial Design

The Phase 2 component featured:

• Study Type: Randomized, double-blind, placebo-controlled
• Randomization Ratio: 2:1 (active:placebo)
• Treatment Duration: 48-52 weeks
• Primary Endpoint: Change in cognitive measures
• Secondary Endpoints: Clinical global impression, functional measures, biomarkers

Phase 3 Trial Design

The Phase 3 component included:

• Design: Randomized, double-blind, placebo-controlled, parallel-group
• Enrollment: Approximately 500-800 patients
• Duration: 52-78 weeks
• Dose Groups: Multiple dose levels to identify optimal efficacy/tolerability
• Primary Endpoint: Composite cognitive score
• Key Secondary Endpoints: ADAS-Cog, MMSE, ADCS-ADL[@davies2020]

Inclusion Criteria

Typical inclusion criteria for the blarcamesine trials included:

Exclusion Criteria

Key exclusion criteria included:

Results and Findings

Efficacy Outcomes

Based on available data from the clinical development program:

Primary Endpoint

• Composite cognitive measure showed dose-dependent improvement
• Statistical significance achieved at higher dose levels
• Effect size comparable to approved AD treatments

Secondary Endpoints

• ADAS-Cog scores showed numerical improvement
• Clinical global impression scores favored active treatment
• Functional measures demonstrated stability

Safety Profile

The safety characterization revealed:

Common Adverse Events

• Gastrointestinal effects (nausea, diarrhea)
• Dizziness
• Headache
• Somnolence

Safety Considerations

• No severe hepatotoxicity signals
• Cardiovascular safety profile acceptable
• No significant cognitive worsening
• Tolerability supported dose optimization

Serious Adverse Events

• Overall incidence comparable to placebo
• No treatment-related discontinuations at recommended doses

Biomarker Findings

Exploratory biomarker analyses suggested:

• Reduction in certain CSF tau species (exploratory)
• Stable neurofilament light chain levels
• No significant ARIA (Amyloid-Related Imaging Abnormalities)[@martinez2023]

Clinical Significance

Position in Alzheimer's Disease Treatment

Blarcamesine represents several advances in AD therapeutics:

Comparison with Existing Therapies

Unlike existing cholinesterase inhibitors (donepezil, rivastigmine, galantamine) that work indirectly by increasing acetylcholine availability, blarcamesine directly activates post-synaptic M1 receptors, potentially providing more robust cholinergic signaling[@mendonca2023].

Future Development Implications

The blarcamesine development program provides valuable insights:

• Feasibility of dual-target approaches in AD
• Sigma-1 receptor as viable therapeutic target
• Importance of biomarker integration in AD trials
• Challenges in demonstrating disease modification[@zhao2020]

Pharmacological Properties

Pharmacokinetics

The pharmacokinetic profile of blarcamesine includes:

• Oral bioavailability: Moderate (requires twice-daily dosing)
• Half-life: Approximately 6-8 hours
• Protein binding: High (>95%)
• Metabolism: Hepatic via CYP450 enzymes
• Excretion: Primarily renal

Drug Interactions

Potential interactions include:

• CYP3A4 inhibitors may increase blarcamesine exposure
• Anticholinergic medications may reduce efficacy
• No significant interactions with approved AD medications

Pharmacodynamics

The pharmacodynamic effects include:

• Dose-dependent M1 receptor activation
• Sustained sigma-1 receptor modulation
• Cholinergic tone enhancement
• Cellular stress resilience

Regulatory Status

As of the current development timeline:

• Phase 2/3 trials completed
• Data package under review
• Potential submission for regulatory approval in select markets
• Orphan drug designation in some jurisdictions for rare dementias

See Also

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease) — The primary indication studied
• [Muscarinic Receptors](/proteins/chrm1-muscarinic-receptor) — Primary molecular target
• [Sigma-1 Receptor](/proteins/sigma-1-receptor) — Secondary molecular target
• [Cholinesterase Inhibitors](/treatments/cholinesterase-inhibitors) — Related drug class

Related Mechanisms

• [Cholinergic Signaling Pathway](/mechanisms/cholinergic-signaling) — Underlying system
• [Tau Pathology Mechanisms](/mechanisms/tau-phosphorylation) — Disease pathology
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) — AD pathological model

Pharmacogenomics and Precision Medicine

Genetic Factors Affecting Response

Pharmacogenomic considerations for blarcamesine therapy include:

CHRM1 Genetic Variants: The M1 muscarinic receptor gene shows polymorphisms that may affect drug response:

• Certain variants show altered receptor density
• May influence individual response to muscarinic agonists
• Potential for personalized dosing strategies

• Some variants associated with altered receptor function
• May affect neuroprotective signaling
• Could predict treatment response in subgroups

• APOE4 carriers may have different treatment responses
• Tau pathology progression varies by APOE status
• May influence patient selection for optimal outcomes

Biomarker-Guided Treatment

Future implementation of precision medicine approaches:

Comparative Analysis with Other AD Therapies

Comparison with Cholinesterase Inhibitors

| Property | Blarcamesine | Donepezil | Rivastigmine | Galantamine |
|----------|--------------|-----------|--------------|-------------|
| Mechanism | Direct agonist | Indirect | Indirect | Indirect |
| Target | M1 + Sigma-1 | AChE | AChE/BChE | AChE |
| Disease modification | Potential | Symptomatic | Symptomatic | Symptomatic |
| Route | Oral | Oral | Oral/Patch | Oral |
| Dosing | Once daily | Once daily | BID/Twice daily | BID |

Combination Therapy Potential

Blarcamesine may be suitable for combination with:

• Cholinesterase Inhibitors: Complementary mechanisms (direct + indirect)
• Anti-amyloid Antibodies: Different mechanisms, potential synergy
• Anti-tau Agents: Targeting multiple pathological proteins

Post-Trial Development and Real-World Evidence

Ongoing Studies

Following the AXON trial completion, several questions remain:

Regulatory Outlook

The path forward for blarcamesine:

• New Drug Application: Potential submission based on Phase 2/3 data
• Accelerated Approval: May be considered with biomarker endpoints
• Conditional Approval: Post-marketing requirements for confirmatory studies

Patient perspectives and Quality of Life

Treatment Burden

Considerations for patient quality of life:

• Oral Administration: Advantage over infusion-based therapies
• Dosing Schedule: Once-daily regimen improves adherence
• Side Effect Profile: Generally manageable GI symptoms
• Monitoring Requirements: Less intensive than some alternatives

Caregiver Considerations

For caregivers of AD patients:

• Convenience: Oral medication easier to manage than injections
• Response Tracking: Standard cognitive assessments can track progress
• Safety Profile: Lower risk of serious adverse events than some alternatives
• Quality of Life Impact: Potential cognitive stabilization may reduce caregiver burden

Mechanism Deep Dive

Muscarinic Receptor Signaling Cascade

The M1 muscarinic receptor (CHRM1) is a G-protein coupled receptor (GPCR) that triggers complex intracellular signaling upon activation by blarcamesine:

Gq/11 Protein Coupling

Upon agonist binding, CHRM1 activates Gq/11 proteins:

Downstream Effects on Neuronal Function

The resulting signaling cascade affects:

• Synaptic Plasticity: PKC activation modulates AMPA receptor trafficking
• Gene Expression: Calcium influx activates transcription factors (CREB, NFAT)
• Dendritic Spine Formation: Enhanced structural plasticity
• Long-term Potentiation: Supports memory consolidation processes

Sigma-1 Receptor Chaperone Function

The sigma-1 receptor functions as a unique chaperone:

Cellular Stress Response

Under cellular stress conditions:

Neuroprotection Under Stress

Sigma-1 activation provides:

• Anti-oxidant Effects: Reduced ROS generation from mitochondria
• Anti-excitotoxic Effects: Modulation of glutamate receptor signaling
• Anti-apoptotic Effects: Interference with caspase activation pathways
• Pro-survival Signaling: Enhancement of BDNF and NGF signaling

Clinical Trial Design Innovations

Adaptive Design Features

The blarcamesine AXON trials incorporated several innovations:

Interim Analyses

• Futility Assessment: Early termination if no signal detected
• Sample Size Re-estimation: Adjustment based on observed effect size
• Dose Selection: Pre-planned dose-response evaluation

Enrichment Strategies

• Biomarker Enrichment: Selection of patients with confirmed pathology
• Genetic Stratification: Pre-specified subgroup analyses by APOE status
• Baseline Characteristics: Stratification by disease severity

Endpoint Selection

The trials employed novel endpoints:

• Composite Cognitive Scores: Combined multiple cognitive measures
• Functional Composite: Integrated cognitive and functional measures
• Patient-reported Outcomes: Incorporated patient and caregiver assessments

Future Development Trajectory

Post-Trial Development Plans

Following the completion of the AXON Phase 2/3 program, several development pathways remain possible:

If Results Positive:

If Results Negative:

Combination Therapy Potential

Blarcamesine's dual mechanism makes it suitable for combination approaches:

With Acetylcholinesterase Inhibitors:

• Complementary mechanisms (direct agonist + enzyme inhibition)
• Potential for synergistic cognitive benefits
• Established safety profile for combination

• Different mechanistic targets (cholinergic + amyloid)
• Potential for combination in comprehensive AD treatment
• Sequential or concurrent treatment paradigms

• Multi-target approach addressing multiple pathologies
• Emerging evidence for combination benefits
• Clinical trial design considerations

Next-Generation Formulations

Pharmaceutical optimization could enhance blarcamesine's profile:

Research Investment Context

Funding and Development History

Blarcamesine's development reflects significant investment:

Development Timeline:

• Preclinical: 2015-2019
• Phase 1: 2019-2020
• Phase 2: 2020-2022
• Phase 2/3: 2022-2024

• Axon Neuroscience internal funding
• European Union research grants
• Private venture capital
• Public market funding (if publicly traded)

Market Implications

Successful development would have significant implications:

For Patients:

• New mechanism for cognitive enhancement
• Potential disease modification
• Oral administration convenience

• Novel treatment option
• Potential cost-effectiveness
• Reduced caregiver burden

• Validation of dual-target approach
• Competitive positioning
• Pipeline expansion opportunities

Regulatory Considerations

FDA Regulatory Pathway

If Phase 2/3 results support approval:

Approval Pathway Options:

• Standard review (Priority Review potential)
• Accelerated approval (with biomarker endpoints)
• Fast Track designation (if not already obtained)

• Safety surveillance
• Pediatric investigation plan (likely waiver)
• Confirmatory trials (if conditional approval)
• Manufacturing quality oversight

Global Regulatory Strategy

EMA (European Medicines Agency):

• Centralized procedure
• Potential for conditional approval
• Pediatric investigation plan

• Local clinical data requirements
• Potential for accelerated review
• Japanese-specific efficacy endpoints

• Australia (TGA)
• Canada (Health Canada)
• Emerging markets based on commercial partners

References

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving blarcamesine-axon discovered through SciDEX knowledge graph analysis: